CAR-T Cell Therapy for Leukemia
CAR-T cell therapy consists of patient-derived T-cells that are genetically modified to express chimeric antigen receptors targeting CD19-positive cancer cells. These engineered cells are used for the treatment of relapsed B-cell acute lymphoblastic leukemia and are classified as cell therapy products under tariff item 3002.51.00.
Import Duty Rates by Country of Origin
| Origin Country | MFN Tariff | Surtaxes | Total Effective Rate |
|---|---|---|---|
| 🇨🇳China | Free | — | Free |
| 🇲🇽Mexico | Free | — | Free |
| 🇺🇸United States | Free | — | Free |
| 🇩🇪Germany | Free | — | Free |
| 🇯🇵Japan | Free | — | Free |
More Specific Codes
This product may fall under a more specific subheading:
Alternative Classifications
This product could be classified differently depending on its characteristics or intended use.
If the CAR-T product is not presented as a cell therapy but as a mixed immunological product.
Covers other immunological products not specifically classified as cell therapy products.
Not sure which classification is right?
The Tariff Assistant works through the GRI rules on your specific product to reach the right tariff item — and can price the duty on it in the same conversation.
Import Tips & Compliance
• Ensure the product is accompanied by a valid Health Canada authorization or clinical trial approval, as cell therapy products are regulated under the Food and Drugs Act
• Provide detailed documentation on the genetic modification process and cell viability to support classification under 3002.51.00
• Coordinate with the CBSA and the Canadian Food Inspection Agency (CFIA) if the product contains animal-derived components
Related Products under Tariff item 3002.51.00
Dendritic Cell Vaccine for Prostate Cancer
Dendritic cell vaccines, such as sipuleucel-T, are autologous dendritic cells loaded with tumor-associated antigens and matured ex vivo for personalized cancer immunotherapy. These modified cell cultures are classified as cell therapy products under tariff item 3002.51.00.
iPSC-Derived Cardiomyocyte Therapy for Heart Failure
iPSC-derived cardiomyocyte therapy involves induced pluripotent stem cells differentiated into cardiomyocytes for injection to repair heart tissue after myocardial infarction. These engineered cell cultures are classified as cell therapy products under tariff item 3002.51.00.
Mesenchymal Stem Cell Therapy for Osteoarthritis
Mesenchymal stem cell therapy uses allogeneic MSCs derived from umbilical cord tissue, expanded and cryopreserved for intra-articular injection to treat knee osteoarthritis. These cell cultures are classified as cell therapy products under tariff item 3002.51.00.
NK Cell Therapy for Solid Tumors
NK cell therapy involves natural killer cells from peripheral blood that are cytokine-activated and expanded for adoptive transfer in treating solid tumors like melanoma. These modified cell cultures are classified as cell therapy products under tariff item 3002.51.00.
Treg Cell Therapy for Autoimmune Diseases
Treg cell therapy involves regulatory T-cells expanded ex vivo from patient blood and modified for enhanced suppressive function to treat graft-versus-host disease. These cell cultures are classified as cell therapy products under tariff item 3002.51.00.